BACKGROUND: Natural killer (NK) cells derived from patients with cancer exhibit diminished cytotoxicity compared with NK cells from healthy individuals. We evaluated the tumor response and in vivo expansion of allogeneic NK cells in recurrent ovarian and breast cancer. METHODS: Patients underwent a lymphodepleting preparative regimen: fludarabine 25 mg/m(2) × 5 doses, cyclophosphamide 60 mg/kg × 2 doses, and, in seven patients, 200 cGy total body irradiation (TBI) to increase host immune suppression. An NK cell product, from a haplo-identical related donor, was incubated overnight in 1000 U/mL interleukin (IL)-2 prior to infusion. Subcutaneous IL-2 (10 MU) was given three times/week × 6 doses after NK cell infusion to promote expansion, defined as detection of ≥100 donor-derived NK cells/μL blood 14 days after infusion, based on molecular chimerism and flow cytometry. RESULTS: Twenty (14 ovarian, 6 breast) patients were enrolled. The median age was 52 (range 30-65) years. Mean NK cell dose was 2.16 × 10(7)cells/kg. Donor DNA was detected 7 days after NK cell infusion in 9/13 (69%) patients without TBI and 6/7 (85%) with TBI. T-regulatory cells (Treg) were elevated at day +14 compared with pre-chemotherapy (P = 0.03). Serum IL-15 levels increased after the preparative regimen (P = <0.001). Patients receiving TBI had delayed hematologic recovery (P = 0.014). One patient who was not evaluable had successful in vivo NK cell expansion. CONCLUSIONS: Adoptive transfer of haplo-identical NK cells after lymphodepleting chemotherapy is associated with transient donor chimerism and may be limited by reconstituting recipient Treg cells. Strategies to augment in vivo NK cell persistence and expansion are needed.
BACKGROUND: Natural killer (NK) cells derived from patients with cancer exhibit diminished cytotoxicity compared with NK cells from healthy individuals. We evaluated the tumor response and in vivo expansion of allogeneic NK cells in recurrent ovarian and breast cancer. METHODS:Patients underwent a lymphodepleting preparative regimen: fludarabine 25 mg/m(2) × 5 doses, cyclophosphamide 60 mg/kg × 2 doses, and, in seven patients, 200 cGy total body irradiation (TBI) to increase host immune suppression. An NK cell product, from a haplo-identical related donor, was incubated overnight in 1000 U/mL interleukin (IL)-2 prior to infusion. Subcutaneous IL-2 (10 MU) was given three times/week × 6 doses after NK cell infusion to promote expansion, defined as detection of ≥100 donor-derived NK cells/μL blood 14 days after infusion, based on molecular chimerism and flow cytometry. RESULTS: Twenty (14 ovarian, 6 breast) patients were enrolled. The median age was 52 (range 30-65) years. Mean NK cell dose was 2.16 × 10(7)cells/kg. Donor DNA was detected 7 days after NK cell infusion in 9/13 (69%) patients without TBI and 6/7 (85%) with TBI. T-regulatory cells (Treg) were elevated at day +14 compared with pre-chemotherapy (P = 0.03). Serum IL-15 levels increased after the preparative regimen (P = <0.001). Patients receiving TBI had delayed hematologic recovery (P = 0.014). One patient who was not evaluable had successful in vivo NK cell expansion. CONCLUSIONS: Adoptive transfer of haplo-identical NK cells after lymphodepleting chemotherapy is associated with transient donor chimerism and may be limited by reconstituting recipient Treg cells. Strategies to augment in vivo NK cell persistence and expansion are needed.
Authors: J S Miller; J Tessmer-Tuck; B A Pierson; D Weisdorf; P McGlave; B R Blazar; E Katsanis; C Verfaillie; J Lebkowski; J Radford; L J Burns Journal: Biol Blood Marrow Transplant Date: 1997-04 Impact factor: 5.742
Authors: Pawel Muranski; Andrea Boni; Claudia Wrzesinski; Deborah E Citrin; Steven A Rosenberg; Richard Childs; Nicholas P Restifo Journal: Nat Clin Pract Oncol Date: 2006-12
Authors: Marc Beyer; Matthias Kochanek; Kamruz Darabi; Alexey Popov; Markus Jensen; Elmar Endl; Percy A Knolle; Roman K Thomas; Michael von Bergwelt-Baildon; Svenja Debey; Michael Hallek; Joachim L Schultze Journal: Blood Date: 2005-05-24 Impact factor: 22.113
Authors: Mei-Ling Chen; Mikaël J Pittet; Leonid Gorelik; Richard A Flavell; Ralph Weissleder; Harald von Boehmer; Khashayarsha Khazaie Journal: Proc Natl Acad Sci U S A Date: 2004-12-27 Impact factor: 11.205
Authors: Melissa A Geller; David A Knorr; David A Hermanson; Lee Pribyl; Laura Bendzick; Valarie McCullar; Jeffrey S Miller; Dan S Kaufman Journal: Cytotherapy Date: 2013-10 Impact factor: 5.414
Authors: Sarah S Donatelli; Jun-Min Zhou; Danielle L Gilvary; Erika A Eksioglu; Xianghong Chen; W Douglas Cress; Eric B Haura; Matthew B Schabath; Domenico Coppola; Sheng Wei; Julie Y Djeu Journal: Proc Natl Acad Sci U S A Date: 2014-02-28 Impact factor: 11.205
Authors: O Adotevi; Y Godet; J Galaine; Z Lakkis; I Idirene; J M Certoux; M Jary; R Loyon; C Laheurte; S Kim; A Dormoy; F Pouthier; C Barisien; F Fein; P Tiberghien; X Pivot; S Valmary-Degano; C Ferrand; P Morel; E Delabrousse; C Borg Journal: Oncoimmunology Date: 2018-03-19 Impact factor: 8.110
Authors: Jeffrey S Miller; Cliona M Rooney; Julie Curtsinger; Ron McElmurry; Valarie McCullar; Michael R Verneris; Natalia Lapteva; David McKenna; John E Wagner; Bruce R Blazar; Jakub Tolar Journal: Biol Blood Marrow Transplant Date: 2014-05-09 Impact factor: 5.742
Authors: Gabriela Maria Wiedemann; Severin Johannes Jacobi; Michael Chaloupka; Angelina Krächan; Svetlana Hamm; Stefan Strobl; Roland Baumgartner; Simon Rothenfusser; Peter Duewell; Stefan Endres; Sebastian Kobold Journal: Oncoimmunology Date: 2016-05-31 Impact factor: 8.110
Authors: Xinxin Song; Se-Hoon Hong; William T Kwon; Lisa M Bailey; Per Basse; David L Bartlett; Yong Tae Kwon; Yong J Lee Journal: Mol Cancer Ther Date: 2016-04-12 Impact factor: 6.261